Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, posted on LinkedIn:
“Proud moment at ASCO25!
Our SAGA Diagnostics poster on tumor-informed ctDNA as a predictive marker for relapse in advanced ovarian cancer drew much interest and discussion.
Findings show that ctDNA clearance at end of chemo (C6) predicts recurrence risk better than CA-125 especially in patients with complete cytoreduction.
Amazing to connect with so many colleagues and showcase the power of Pathlight MRD technology by Team SAGA.
Thank you for the support and enthusiasm!”
More posts featuring Daniel Sumarriva on OncoDaily.